Alphavirus replicon vector systems

Details Alphavirus replicon vector systems Alphavirus replicon vector systems

2006-05-16

2006-05-16

Mosher, Mary E. (Department: 1648)

Chemistry: molecular biology and microbiology

Virus or bacteriophage, except for viral vector or...

C435S239000, C435S461000, C435S325000, C435S369000, C435S352000, C435S364000, C435S358000, C435S320100, C435S252300, C536S023720

Reexamination Certificate

active

07045335

ABSTRACT:
The present invention provides compositions useful in and methods for producing populations of infectious, replication-defective alphavirus replicon particles that contain no replication-competent alphavirus particles, as determined by passage on cells in culture. The compositions include helper and replicon nucleic acid molecules that can further reduce the predicted frequency for formation of replication-competent virus and can optimize manufacturing strategies and costs.

REFERENCES:
patent: 4650764 (1987-03-01), Temin
patent: 4708871 (1987-11-01), Geysen
patent: 5091309 (1992-02-01), Schlesinger
patent: 5185440 (1993-02-01), Davis
patent: 5217879 (1993-06-01), Huang
patent: 5505947 (1996-04-01), Johnston
patent: 5521082 (1996-05-01), Lewis et al.
patent: 5639650 (1997-06-01), Johnston
patent: 5643576 (1997-07-01), Johnston
patent: 5703057 (1997-12-01), Johnston et al.
patent: 5726022 (1998-03-01), Burmer
patent: 5739026 (1998-04-01), Garoff
patent: 5766602 (1998-06-01), Xiong
patent: 5789245 (1998-08-01), Dubensky et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5811407 (1998-09-01), Johnston
patent: 5814482 (1998-09-01), Dubensky
patent: 5827658 (1998-10-01), Liang
patent: 5831016 (1998-11-01), Wang et al.
patent: 5843723 (1998-12-01), Dubensky
patent: 5853719 (1998-12-01), Nair et al.
patent: 5958738 (1999-09-01), Lindermann et al.
patent: 5989553 (1999-11-01), Johnston et al.
patent: 6008035 (1999-12-01), Johnston
patent: 6015686 (2000-01-01), Dubensky
patent: 6015694 (2000-01-01), Dubensky
patent: 6146874 (2000-11-01), Zolotukhin
patent: 6156558 (2000-12-01), Johnston
patent: 6190666 (2001-02-01), Garoff
patent: 6194191 (2001-02-01), Zhang et al.
patent: 6197502 (2001-03-01), Renner et al.
patent: 6224879 (2001-05-01), Sjoberg
patent: 6242259 (2001-06-01), Polo et al.
patent: 6261570 (2001-07-01), Parker
patent: 6267967 (2001-07-01), Johnston et al.
patent: 6306388 (2001-10-01), Nair et al.
patent: 6329201 (2001-12-01), Polo
patent: 6342372 (2002-01-01), Dubensky
patent: 6495143 (2002-03-01), Lee et al.
patent: 6376236 (2002-04-01), Dubensky
patent: 6391632 (2002-05-01), Dubensky
patent: 6426196 (2002-07-01), Dubensky et al.
patent: 6485958 (2002-11-01), Blanch et al.
patent: 6521235 (2003-02-01), Johnston et al.
patent: 6531135 (2003-03-01), Johnston et al.
patent: 6541010 (2003-04-01), Johnston et al.
patent: 6583121 (2003-06-01), Johnston et al.
patent: 6767699 (2004-07-01), Polo et al.
patent: 6770283 (2004-08-01), Garoff et al.
patent: 6783939 (2004-08-01), Olmsted et al.
patent: 6844188 (2005-01-01), MacDonald et al.
patent: 2001/0016199 (2001-08-01), Johnston et al.
patent: 2002/0018766 (2002-02-01), Roberts et al.
patent: 2002/0034521 (2002-03-01), Lee et al.
patent: 2002/0102273 (2002-08-01), Grieve et al.
patent: 2002/0141975 (2002-10-01), Olmsted et al.
patent: 2002/0164582 (2002-11-01), Hart et al.
patent: 2003/0021766 (2003-01-01), Vadjy et al.
patent: 2003/0091591 (2003-05-01), Xiong et al.
patent: 2003/0096397 (2003-05-01), Schlesinger et al.
patent: 2003/0119182 (2003-06-01), Smith et al.
patent: 2003/0120060 (2003-06-01), Gonczol et al.
patent: 2003/0152590 (2003-08-01), Hevey et al.
patent: 2003/0232036 (2003-12-01), Johnston et al.
patent: 2004/0008458 (2004-01-01), Kase et al.
patent: 2004/0009183 (2004-01-01), Lee et al.
patent: 2004/0009945 (2004-01-01), Lee et al.
patent: 2004/0029279 (2004-02-01), Kovacs et al.
patent: 2004/0030117 (2004-02-01), Johnston et al.
patent: 2004/0121466 (2004-06-01), Johnston et al.
patent: 2004/0146859 (2004-07-01), Hart et al.
patent: 2004/0166573 (2004-08-01), Smith et al.
patent: 2004/0208848 (2004-10-01), Smith et al.
patent: 2005/0031592 (2005-02-01), Doolan et al.
patent: 2005/0054107 (2005-03-01), Chulay et al.
patent: 2005/0118251 (2005-06-01), Nagata et al.
patent: WO 02/10578 (1992-06-01), None
patent: WO 92/10578 (1992-06-01), None
patent: WO 95/07994 (1995-03-01), None
patent: WO 95/27044 (1995-10-01), None
patent: WO 95/31565 (1995-11-01), None
patent: WO 96/17072 (1996-06-01), None
patent: WO 96/37220 (1996-11-01), None
patent: WO 96/37616 (1996-11-01), None
patent: WO 99/07834 (1999-02-01), None
patent: WO 99/08706 (1999-02-01), None
patent: WO 00/39302 (2000-07-01), None
patent: WO 00/39318 (2000-07-01), None
patent: WO 00/61772 (2000-10-01), None
patent: WO 01/16343 (2001-03-01), None
patent: WO 02/003917 (2002-01-01), None
patent: WO 02/04493 (2002-01-01), None
patent: WO 02/20721 (2002-03-01), None
patent: WO 03/023026 (2003-03-01), None
patent: WO 03/083065 (2003-10-01), None
patent: WO 04/055166 (2004-07-01), None
patent: WO 04/055167 (2004-07-01), None
patent: WO 04/085660 (2004-10-01), None
patent: WO 05/007689 (2005-01-01), None
Product Descriptions, ATCC CRL-11268 and ATCC CRL 12203 [retrieved on Apr. 29, 2005]. Retrieved from the Internet <URL:http://www.atcc.org/catalog
umSearch
umResults.cfm>.
Caley et al., “Venezuelan Equine Encephalitis Virus Vectors Expressing HIV-1 Proteins: Vector Design Strategies for Improved Vaccine Efficacy,”Vaccine, 17:3124-3135 (1999).
Li et al., “Production of Infectious Recombinant Moloney Murine Leukemia Virus Particles in BHK Cells Using Semliki Forest Virus-Derived RNA Expression Vectors,”Proc. Natl. Acad. Sci. USA, 93 11658-11663 (Oct. 1996).
Weiss and Schlesinger. 1991. Recombination between Sindbis Virus RNAs.Journal of Virology65 4017-4025.
Barouch et al. 2000. Augmentation of Immune Responses to HIV-1 and Simian Immunodeficiency Virus DNA Vaccines by IL-2/lg Plasmid Administration in Rhesus Monkeys.PNAS97(8): 4192-4197.
Feyzi et al. 1997. Structural Requirement of Heparan Sulfate for Interaction with Herpes Simplex Virus Type 1 Virions and Isolated Glycoprotein C.The Journal of Biological Chemistry272(40):24850-24857.
Herweijer et al. 1997. Self-Amplifying Vectors for Gene Delivery.Advanced Drug Delivery Reviews27:5-16.
Kondor-Koch et al. 1983. Expression of Semliki Forest Virus Proteins from Cloned Complementary DNA. I. The Fusion Activity of the Spike Glycoprotein.J. Cell Biology97(3):644-651.
Lee et al. 1997. Efficient Long-Term Coexpression of a Hammerhead Ribozyme Targeted to the U5 Region of HIV-1 LTR by Linkage to the Multidrug-Resistance Gene.Antisense&Nucleic Acid Drug Development7:511-522.
Leone et al. 1985. In Vitro Synthesis of the Gene Coding for the Glycoprotein E1 of Sindbis Virus.Microbiologica8(2):123-130.
Oker-Blom et al. 1989. Expression of Sindbis Virus 26S cDNA inSpodoptera frugiperda(Sf9) Cells, Using a Baculovirus Expression Vector.J. Virology63:1256-1264.
Orkin et al. 1995. Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy.
Rice et al. 1985. Expression of Sindbis Virus Structural Proteins via Recombinant Vaccinia Virus: Synthesis, Processing, and Incorporation into Mature Sindbis Virions.J. Virology56:227-239.
Strauss and Strauss. 1990. Alphavirus Proteinases.Seminars In Virology1:347-356.
Sykes and Johnston. 1999. Genetic Live Vaccines Mimic the Antigenicity but Not Pathogenicity of Live Viruses.DNA and Cell Biology.18(7):521-531.
Ute Geigenmuller-Gnirke et al. 1991. Complementation Between Sindbis Viral RNAs Produces Infectious Particles with a Bipartite Genome.Proceedings of the National Academy of Sciences88:3253-3257.
Verma et al. 1997. Gene Therapy—Promises, Problems and Prospects.Nature389:239-242.
International Search Report of International Application Serial No. PCT/US02/28610 filed Sep. 6, 2002.
Anu Jalanko. 1985. Expression of Semliki Forest Virus Capsid Protein from SV40 Recombinant Virus.FEBS Letters186:59-64.
Berglund et al. 1993. Semliki Forest Virus Expression System: Production of Conditionally Infectious Recombinant Particles,Bio/Technology11:916-920.
Betts et al. 1997. Cross-Clade Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Responses in HIV-Infected Zambians.J. Virol.71(11):8908-8911.
Bredenbeek et al. 1993. Sindbis Virus Expression Vectors: Packaging of RNA Replicons by Using Defective Helper RNAs.Journal of Virology67:6439-6446.
Caley et al. 1997. Humoral, Mucosal, and Cellu

Affiliated with

Also associated with

Rating

Alphavirus replicon vector systems does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alphavirus replicon vector systems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alphavirus replicon vector systems will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3632069